RENOVORX INC (RNXT) Stock News
NASDAQ:RNXT - Nasdaq - US75989R1077 - Common Stock - Currency: USD
RNXT Latest News and Analysis
What's going on in today's pre-market session
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
These stocks are moving in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
RenovoRx Announces Proposed Public Offering
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System
Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy RenovoRx Estimates...
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in...
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights...
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of...
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York
LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical...
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024...
RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024
RNXT stock results show that RenovoRx met analyst estimates for earnings per share the second quarter of 2024.
RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips RenovoRx (NASDAQ:RNXT) just reported results for the second quarter of 2024.Ren...
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®
Publication of data relating to RenovoRx’s targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the...
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial
Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer...
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
New role highlights RenovoRx’s commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic...
RenovoRx CEO Issues Update Letter to Shareholders
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024
RNXT stock results show that RenovoRx beat analyst estimates for earnings per share the first quarter of 2024.
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning!
RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023
RNXT stock results show that RenovoRx met analyst estimates for earnings per share the fourth quarter of 2023.
RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips RenovoRx (NASDAQ:RNXT) just reported results for the fourth quarter of 2023.Ren...